<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282293</url>
  </required_header>
  <id_info>
    <org_study_id>PROMOTE-BC2</org_study_id>
    <nct_id>NCT02282293</nct_id>
  </id_info>
  <brief_title>Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)</brief_title>
  <official_title>Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, randomized controlled trial of 200 HIV-infected pregnant women
      living in Tororo, Uganda, an area of high malaria transmission. HIV-infected pregnant women
      between 12 and 28 weeks gestation will be randomized to receive enhanced malaria
      chemoprevention with monthly dihydroartemisinin-piperaquine (DP) versus monthly DP placebo.
      Their HIV-exposed children will receive the same prevention regimen from 2 to 24 months of
      age to which the mothers were randomized. All women will receive daily
      trimethoprim-sulfamethoxazole (TS) throughout the study per Uganda Ministry of Health
      guidelines. Children will also receive daily TS from 6 weeks to 24 months of age. TS will be
      considered a study drug only in infants and children beginning 6 weeks after cessation of
      breastfeeding and upon exclusion of HIV infection. Women and their children will be followed
      for 36 months after delivery. In a subset of the study population, the investigators will
      conduct an intensive pharmacokinetic study that will evaluate pharmacokinetic exposure of DP
      and EFV. The investigators will also measure HIV-related outcomes among the women enrolled in
      the study. The investigators will test the hypothesis that for HIV-infected mothers and
      HIV-exposed infants, that enhanced versus standard malaria chemoprevention in HIV-infected
      pregnant women and their children will reduce the incidence of malaria among children from 0
      to 24 months of age and improve the development of naturally acquired antimalarial immunity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women will be scheduled to be seen in the study clinic every 4 weeks during their
      pregnancy. Women will be seen at 1 week, 6 weeks, and 3 months postpartum and every 3 months
      thereafter. In addition, pregnant women will be instructed to come to the study clinic for
      all their medical care and avoid the use of any outside medications. Women will be provided
      all routine HIV care at the clinic according to Uganda MOH guidelines. All women will have
      ARVs and TS dispensed at the study clinic. Counseling on breastfeeding and infant feeding
      will be provided per Uganda MOH guidelines. HIV care and breastfeeding and infant feeding
      recommendations may be changed to reflect the most recent standard of care per MOH
      guidelines. Children will be scheduled to be seen in the clinic every 4 weeks and parents
      /guardians of children will be instructed to bring their child to the study clinic for all
      medical care and avoid the use of any outside medications. The study clinic will remain open
      7 days a week from 8 a.m. to 5 p.m.

      Each time a study participant is seen in the clinic a standardized history and physical exam
      will be performed. Patients who are febrile (tympanic temperature &gt; 3 8.0˚C) or report
      history of fever in the past 24 hours will have blood obtained by finger prick for a thick
      blood smear. If the thick blood smear is positive, the patient will be diagnosed with
      malaria. If the thick blood smear is negative, the patient will be managed by study
      physicians for a non-malarial febrile illness. If the patient is afebrile and does not report
      a recent fever, a thick blood smear will not be obtained, except when following routine
      testing schedules.

      Routine assessments will be done in the clinic every 4 weeks for both pregnant women and
      children. Pregnant women and children will receive standards of care as designated in the
      Uganda MOH guidelines. Children will have care for HIV-exposed children according to MOH
      guidelines, with the exception that TS will be continued until 2 years of life. Routine care
      in children will use Integrated Management of Childhood Illness (IMCI) guidelines. During
      routine assessments subjects will be asked about visits to outside health facilities and the
      use of any medications outside the study protocol. Standardized assessment of adherence will
      also be done for study drugs administered at home and Insecticide Treated Net use. A routine
      history and physical exam will be performed using a standardized clinical assessment form.
      Blood will be collected by finger prick for thick smear, collection of plasma for PK studies,
      and filter paper samples. Phlebotomy for routine laboratory tests (CBC and ALT) to monitor
      for potential adverse events from study medications and for immunology studies will be
      performed every 8 weeks in pregnant women. Non malaria screening will also include stool ova
      and parasite examination, circulating filarial antigens (by ICT card for Wucheria), and blood
      smear for microfilaremia (including Mansonella perstans) using Knott's technique. For
      pregnant women, study drugs will be administered at the time of each routine visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2014</start_date>
  <completion_date type="Actual">May 26, 2016</completion_date>
  <primary_completion_date type="Actual">May 26, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Placental Malaria</measure>
    <time_frame>at delivery estimated to be within 10 to 30 weeks of study entry</time_frame>
    <description>The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Malaria, Pregnant Women</measure>
    <time_frame>Time at risk will begin following administration of first dose of study drug to delivery</time_frame>
    <description>The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Parasitemia at Delivery by Microscopy and LAMP</measure>
    <time_frame>At delivery</time_frame>
    <description>Proportion of women with parasitemia detected by microscopy or LAMP at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)</measure>
    <time_frame>At delivery</time_frame>
    <description>Proportion of placental blood samples positive for malaria by microscopy or PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Monthly Routine Visits With Positive Blood Samples for Parasites</measure>
    <time_frame>Following administration of first dose of study drug to delivery</time_frame>
    <description>Proportion of monthly routine blood samples positive by LAMP for parasites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Adverse Birth Outcome (Proportion With Low Birth Weight (&lt;2500 gm), Spontaneous Abortion (&lt;28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (&lt;37 Weeks)</measure>
    <time_frame>At delivery</time_frame>
    <description>Proportion with low birth weight (&lt;2500 gm), spontaneous abortion (&lt;28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (&lt;37 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia</measure>
    <time_frame>Following administration of first dose of study drugs to delivery</time_frame>
    <description>Anemia (hemoglobin less than 11g/dL) measured every 8 weeks during pregnancy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Malaria</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Daily TS + Monthly DP pregnancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily TS + DP Placebo pregnancy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)</intervention_name>
    <arm_group_label>Daily TS + Monthly DP pregnancy</arm_group_label>
    <other_name>Duo-Cotexin (Holley-Cotec)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)</intervention_name>
    <arm_group_label>Daily TS + DP Placebo pregnancy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Intrauterine pregnancy confirmed by ultrasound

          2. Estimated gestational age between 12-28 weeks

          3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test

          4. 16 years of age or older

          5. Residency within 30 km of the study clinic

          6. Provision of informed consent

          7. Agreement to come to the study clinic for any febrile episode or other illness and
             avoid medications given outside the study protocol

          8. Plan to deliver in the hospital

        Exclusion Criteria:

          1. History of serious adverse event to TS or DP

          2. Refusal to take cART during pregnancy or as part of routine HIV care

          3. Active medical problem requiring inpatient evaluation at the time of screening

          4. Intention of moving more than 30 km from the study clinic

          5. Active WHO stage 4 condition not stable under treatment

          6. Signs or symptoms of early or active labor

          7. Currently on ritonavir

          8. Currently taking drugs associated with known risk of Torsades de pointes

          9. Currently taking CYP3A inhibitor medications which potentially inhibit the metabolism
             of piperaquine

         10. History of cardiac problems or fainting
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane V Havlir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses R Kamya, MBChB, MMed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University; Infectious Diseases Research Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDRC Research Clinic - Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep;102(3):520-528. doi: 10.1002/cpt.664. Epub 2017 May 30.</citation>
    <PMID>28187497</PMID>
  </reference>
  <reference>
    <citation>Sonoiki E, Nsanzabana C, Legac J, Sindhe KM, DeRisi J, Rosenthal PJ. Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01949-16. doi: 10.1128/AAC.01949-16. Print 2017 Jan.</citation>
    <PMID>27821443</PMID>
  </reference>
  <results_reference>
    <citation>Natureeba P, Kakuru A, Muhindo M, Ochieng T, Ategeka J, Koss CA, Plenty A, Charlebois ED, Clark TD, Nzarubara B, Nakalembe M, Cohan D, Rizzuto G, Muehlenbachs A, Ruel T, Jagannathan P, Havlir DV, Kamya MR, Dorsey G. Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women. J Infect Dis. 2017 Jul 1;216(1):29-35. doi: 10.1093/infdis/jix110.</citation>
    <PMID>28329368</PMID>
  </results_reference>
  <results_reference>
    <citation>Prahl M, Jagannathan P, McIntyre TI, Auma A, Wamala S, Nalubega M, Musinguzi K, Naluwu K, Sikyoma E, Budker R, Odorizzi P, Kakuru A, Havlir DV, Kamya MR, Dorsey G, Feeney ME. Sex Disparity in Cord Blood FoxP3(+) CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis. 2017 Feb 11;4(1):ofx022. doi: 10.1093/ofid/ofx022. eCollection 2017 Winter.</citation>
    <PMID>28480292</PMID>
  </results_reference>
  <results_reference>
    <citation>Odorizzi PM, Feeney ME. Impact of In Utero Exposure to Malaria on Fetal T Cell Immunity. Trends Mol Med. 2016 Oct;22(10):877-888. doi: 10.1016/j.molmed.2016.08.005. Epub 2016 Sep 7. Review.</citation>
    <PMID>27614925</PMID>
  </results_reference>
  <results_reference>
    <citation>Prahl M, Jagannathan P, McIntyre TI, Auma A, Farrington L, Wamala S, Nalubega M, Musinguzi K, Naluwu K, Sikyoma E, Budker R, Vance H, Odorizzi P, Nayebare P, Ategeka J, Kakuru A, Havlir DV, Kamya MR, Dorsey G, Feeney ME. Timing of in utero malaria exposure influences fetal CD4 T cell regulatory versus effector differentiation. Malar J. 2016 Oct 7;15(1):497.</citation>
    <PMID>27717402</PMID>
  </results_reference>
  <results_reference>
    <citation>Roh ME, Shiboski S, Natureeba P, Kakuru A, Muhindo M, Ochieng T, Plenty A, Koss CA, Clark TD, Awori P, Nakalambe M, Cohan D, Jagannathan P, Gosling R, Havlir DV, Kamya MR, Dorsey G. Protective Effect of Indoor Residual Spraying of Insecticide on Preterm Birth Among Pregnant Women With HIV Infection in Uganda: A Secondary Data Analysis. J Infect Dis. 2017 Dec 19;216(12):1541-1549. doi: 10.1093/infdis/jix533.</citation>
    <PMID>29029337</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <results_first_submitted>September 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Diana Havlir</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chemoprevention</keyword>
  <keyword>Malaria</keyword>
  <keyword>Uganda</keyword>
  <keyword>Dihydroartemisinin-piperaquine</keyword>
  <keyword>Trimethoprim-sulfamethoxazole</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TS + DP Placebo Pregnancy</title>
          <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Daily TS + Monthly DP Pregnancy</title>
          <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to comply with study procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TS + DP Placebo Pregnancy</title>
          <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Daily TS + Monthly DP Pregnancy</title>
          <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="5.8"/>
                    <measurement group_id="B2" value="29.8" spread="6.8"/>
                    <measurement group_id="B3" value="30.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age (cont)</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="4.1"/>
                    <measurement group_id="B2" value="19.9" spread="4.5"/>
                    <measurement group_id="B3" value="19.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age (cat)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>12-16 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 16-20 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 20 - 24 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 24 - 28 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gravidity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 pregnancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 pregnancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 3 pregnancies</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insecticide-treated bednet (ITN) ownership</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Household Wealth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lowest Tertile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Middle Tertile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Highest Tertile</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving TMP-SMX prophylaxis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving ART</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell count, cells/mm^3</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500" lower_limit="392" upper_limit="622"/>
                    <measurement group_id="B2" value="516" lower_limit="368" upper_limit="660"/>
                    <measurement group_id="B3" value="516" lower_limit="372" upper_limit="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV load below limit of detection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO HIV disease stage</title>
          <description>WHO clinical staging of HIV/AIDS is defined in the following document: https://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf
In brief:
Stage 1. Asymptomatic Stage 2. Minor infections or &lt;10% weight loss Stage 3. TB, bacterial infections; systemic symptoms or laboratory values of chronic illness Stage 4. Opportunistic infections or cancers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>WHO Stage 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHO Stage 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHO Stage 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHO Stage 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Detection of malaria parasites by LAMP</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Placental Malaria</title>
        <description>The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection.</description>
        <time_frame>at delivery estimated to be within 10 to 30 weeks of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Placental Malaria</title>
          <description>The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>Calculated p-value</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>7.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Malaria, Pregnant Women</title>
        <description>The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
        <time_frame>Time at risk will begin following administration of first dose of study drug to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Malaria, Pregnant Women</title>
          <description>The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
          <units>Events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Parasitemia at Delivery by Microscopy and LAMP</title>
        <description>Proportion of women with parasitemia detected by microscopy or LAMP at delivery</description>
        <time_frame>At delivery</time_frame>
        <population>Out of all 100 enrolled women in each arm: two women in TS+Placebo arm did not have maternal blood specimens collected to analyze; One participant in Daily TS + Monthly DP pregnancy arm did not have blood slide completed for microscopy results but did have blood spot collected for LAMP analysis</population>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Parasitemia at Delivery by Microscopy and LAMP</title>
          <description>Proportion of women with parasitemia detected by microscopy or LAMP at delivery</description>
          <population>Out of all 100 enrolled women in each arm: two women in TS+Placebo arm did not have maternal blood specimens collected to analyze; One participant in Daily TS + Monthly DP pregnancy arm did not have blood slide completed for microscopy results but did have blood spot collected for LAMP analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Microscopy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>7.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)</title>
        <description>Proportion of placental blood samples positive for malaria by microscopy or PCR</description>
        <time_frame>At delivery</time_frame>
        <population>Out of all 100 enrolled women in each arm: four women in TS+Placebo arm and two women in TS+DP arm did not have placental blood specimens collected to analyze; One participant TS+Placebo arm did not have microscopy results; Only one placental blood specimen was collected for each woman</population>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)</title>
          <description>Proportion of placental blood samples positive for malaria by microscopy or PCR</description>
          <population>Out of all 100 enrolled women in each arm: four women in TS+Placebo arm and two women in TS+DP arm did not have placental blood specimens collected to analyze; One participant TS+Placebo arm did not have microscopy results; Only one placental blood specimen was collected for each woman</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Microscopy of placental blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMP analysis of placental blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Monthly Routine Visits With Positive Blood Samples for Parasites</title>
        <description>Proportion of monthly routine blood samples positive by LAMP for parasites</description>
        <time_frame>Following administration of first dose of study drug to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Monthly Routine Visits With Positive Blood Samples for Parasites</title>
          <description>Proportion of monthly routine blood samples positive by LAMP for parasites</description>
          <units>visits with positive blood sample</units>
          <param>Count of Units</param>
          <units_analyzed>visits with positive blood sample</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>visits with positive blood sample</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>Calculated p-value</p_value_desc>
            <method>GEE</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Adverse Birth Outcome (Proportion With Low Birth Weight (&lt;2500 gm), Spontaneous Abortion (&lt;28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (&lt;37 Weeks)</title>
        <description>Proportion with low birth weight (&lt;2500 gm), spontaneous abortion (&lt;28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (&lt;37 weeks)</description>
        <time_frame>At delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Adverse Birth Outcome (Proportion With Low Birth Weight (&lt;2500 gm), Spontaneous Abortion (&lt;28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (&lt;37 Weeks)</title>
          <description>Proportion with low birth weight (&lt;2500 gm), spontaneous abortion (&lt;28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (&lt;37 weeks)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia</title>
        <description>Anemia (hemoglobin less than 11g/dL) measured every 8 weeks during pregnancy</description>
        <time_frame>Following administration of first dose of study drugs to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS + DP Placebo Pregnancy</title>
            <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Daily TS + Monthly DP Pregnancy</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia</title>
          <description>Anemia (hemoglobin less than 11g/dL) measured every 8 weeks during pregnancy</description>
          <units>Routine visit done every 8 weeks</units>
          <param>Count of Units</param>
          <units_analyzed>Routine visit done every 8 weeks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Routine visit done every 8 weeks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Following administration of first study drug to 6 weeks postpartum</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TS + DP Placebo Pregnancy</title>
          <description>Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Daily TS + Monthly DP Pregnancy</title>
          <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines.
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="40" subjects_at_risk="100"/>
                <counts group_id="E2" events="45" subjects_affected="38" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="85" subjects_affected="68" subjects_at_risk="100"/>
                <counts group_id="E2" events="74" subjects_affected="63" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="69" subjects_affected="41" subjects_at_risk="100"/>
                <counts group_id="E2" events="55" subjects_affected="43" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT level</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Dorsey</name_or_title>
      <organization>UCSF</organization>
      <phone>415-206-4680</phone>
      <email>grant.dorsey@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

